AllerGene AI Therapeutics Founder and CEO Sid Kerkar to Present In Vivo Mast Cell-Targeting CAR Technology at Hanson Wade Summit
Presentation will highlight a first-in-class in vivo mRNA-LNP CAR-T approach designed to selectively target disease-driving mast cells as a potential treatment for mastocytosis, chronic urticaria, food allergies, allergic asthma, anaphylaxis, and other mast cell-mediated diseases MIAMI,...
Presentation will highlight a first-in-class in vivo mRNA-LNP CAR-T approach designed to selectively target disease-driving mast cells as a potential treatment for mastocytosis, chronic urticaria, food allergies, allergic asthma, anaphylaxis, and other mast cell-mediated diseases MIAMI,...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.